Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) Director Eric Sachetta purchased 9,708 shares of the stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average cost of $3.29 per share, for a total transaction of $31,939.32. Following the completion of the acquisition, the director directly owned 219,018 shares of the company’s stock, valued at approximately $720,569.22. This trade represents a 4.64% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.
Eric Sachetta also recently made the following trade(s):
- On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The stock was bought at an average price of $3.18 per share, with a total value of $34,741.50.
- On Monday, August 24th, Eric Sachetta acquired 34,697 shares of Sensus Healthcare stock. The shares were bought at an average price of $3.25 per share, for a total transaction of $112,765.25.
Sensus Healthcare Price Performance
SRTS opened at $3.52 on Friday. Sensus Healthcare, Inc. has a 1-year low of $2.66 and a 1-year high of $5.49. The company has a market capitalization of $57.95 million, a price-to-earnings ratio of -3.74 and a beta of 1.10. The business has a 50 day moving average price of $3.05 and a two-hundred day moving average price of $3.52.
Wall Street Analyst Weigh In
SRTS has been the subject of a number of research reports. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Lake Street Capital reduced their target price on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Weiss Ratings cut shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $5.83.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. State Street Corp boosted its stake in Sensus Healthcare by 5.2% during the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after buying an additional 3,400 shares in the last quarter. Geode Capital Management LLC increased its stake in Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after acquiring an additional 3,766 shares during the period. Sachetta LLC increased its stake in Sensus Healthcare by 6.8% in the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after acquiring an additional 9,500 shares during the period. EP Wealth Advisors LLC acquired a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $49,000. Finally, XTX Topco Ltd bought a new stake in Sensus Healthcare in the fourth quarter valued at $77,000. Institutional investors and hedge funds own 25.30% of the company’s stock.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.
Featured Stories
- Five stocks we like better than Sensus Healthcare
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
